keyword
https://read.qxmd.com/read/38703387/psilocybin-reduces-alcohol-self-administration-via-selective-left-nucleus-accumbens-activation-in-rats
#1
JOURNAL ARTICLE
Jérôme Jeanblanc, Romain Bordy, Grégory Fouquet, Virginie Jeanblanc, Mickaël Naassila
The use of psilocybin to treat alcohol use disorder is very promising, but the mechanisms of action remain poorly understood. We combined behavioral, pharmacological and gene expression analyses to decipher the mechanisms of action of psilocybin, for the first time injected into the brain. Male Long Evans rats underwent chronic operant ethanol self-administration before testing the effect of intraperitoneal psilocybin or directly within the nucleus accumbens core or the ventral tegmental area. Transcripts from the dopaminergic system were quantified in the nucleus accumbens and prefrontal cortex...
May 4, 2024: Brain
https://read.qxmd.com/read/38702496/personality-traits-explain-the-relationship-between-psychedelic-use-and-less-depression-in-a-comparative-study
#2
COMPARATIVE STUDY
David K Sjöström, Emma Claesdotter-Knutsson, Petri J Kajonius
Interest in psychedelics is increasing due to the potential for improved mental health and quality of life. However, adverse effects on mental health are still a concern. Personality traits have been suggested to both influence the psychedelic experience and mental health, and even be changed by psychedelic use. The present study describes for the first time a national sample of Swedish psychedelic users (n = 400) compared to a sex and age-matched control-group of non-users (n = 400) regarding mental health variables (depression, insomnia, problematic alcohol and drug use, and dissociation) and personality (Big Five)...
May 3, 2024: Scientific Reports
https://read.qxmd.com/read/38699449/palliative-care-patients-attitudes-and-openness-towards-psilocybin-assisted-psychotherapy-for-existential-distress
#3
JOURNAL ARTICLE
Julia Ruixi Wang, Samuel J Mendez Araque, Gina Micciche, Andrew McMillan, Emily Coughlin, Rosalie Mattiola, Diana English, Kristopher Kaliebe
INTRODUCTION: Patients with incurable illnesses often experience existential distress, profoundly impacting their well-being. Current medical approaches have limitations in addressing these burdens. Psilocybin, a promising psychedelic compound, may offer therapeutic benefits. This pilot survey study aimed to investigate the attitudes and openness toward psilocybin-assisted psychotherapy (PAT) among patients with incurable illnesses. The objective is to assess patients' attitudes toward PAT and identify potential barriers and concerns, including exploring the association between beliefs in psilocybin's therapeutic benefits and interest in receiving this treatment...
2024: Frontiers in Psychiatry
https://read.qxmd.com/read/38698823/effects-of-psilocybin-psychedelic-mushroom-extract-and-5-hydroxytryptophan-on-brain-immediate-early-gene-expression-interaction-with-serotonergic-receptor-modulators
#4
JOURNAL ARTICLE
Elad Lerer, Alexander Botvinnik, Orr Shahar, Meitar Grad, Karin Blakolmer, Noam Shomron, Amit Lotan, Bernard Lerer, Tzuri Lifschytz
Background: Immediate early genes (IEGs) are rapidly activated and initiate diverse cellular processes including neuroplasticity. We report the effect of psilocybin (PSIL), PSIL-containing psychedelic mushroom extract (PME) and 5-hydroxytryptophan (5-HTP) on expression of the IEGs, cfos, egr1 , and egr2 in mouse somatosensory cortex (SSC). Methods: In our initial experiment, male C57Bl/6j mice were injected with PSIL 4.4 mg/kg or 5-HTP 200 mg/kg, alone or immediately preceded by serotonergic receptor modulators...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38697188/at-the-forefront-social-workers-role-in-psilocybin-treatment-for-depression-and-substance-misuse
#5
JOURNAL ARTICLE
Claire Parker, Bethany Marie Wood
This article underscores the critical role of social workers in harnessing the potential therapeutic benefits of psilocybin for treating major depressive disorder (MDD) and substance use disorder (SUD). Contemporary treatments for MDD often have side effects, and the success rate for SUD treatments remains low. The pervasiveness of MDD, combined with the challenges in treating SUD, highlights a need for innovative treatments. This article provides an overview of the resurgence of literature over the past two decades that illuminates the therapeutic promise of psilocybin for mental health treatment; clinical trials elucidate the efficacy of psilocybin-assisted therapy in mitigating MDD and demonstrate great promise in reducing SUD symptoms...
May 2, 2024: Social Work
https://read.qxmd.com/read/38695483/exploring-cultural-competence-inclusivity-and-diversity-in-ketamine-assisted-psychotherapy-a-phenomenological-study
#6
JOURNAL ARTICLE
Dave Rojas, Diane C Zelman, Alexander O Hauson, Irina Alexander
Black, Indigenous, and People of Color (BIPOC), and other minoritized populations are insufficiently represented in research on therapeutic psychedelics. This research was a phenomenological qualitative exploration of a culturally diverse (Hispanic, African American, Asian, Native American, biracial, or LGBTQIA+) and low-income sample of 15 individuals receiving ketamine-assisted psychotherapy (KAP) at a sliding-scale fee community clinic. Participants were interviewed after a ketamine session, after a ketamine integration session, and one month later...
May 2, 2024: Journal of Psychoactive Drugs
https://read.qxmd.com/read/38695382/the-hopkins-oxford-psychedelics-ethics-hope-working-group-consensus-statement
#7
EDITORIAL
Edward Jacobs, Brian D Earp, Paul S Appelbaum, Lori Bruce, Ksenia Cassidy, Yuria Celidwen, Katherine Cheung, Sean K Clancy, Neşe Devenot, Jules Evans, Holly Fernandez Lynch, Phoebe Friesen, Albert Garcia Romeu, Neil Gehani, Molly Maloof, Olivia Marcus, Ole Martin Moen, Mayli Mertens, Sandeep M Nayak, Tehseen Noorani, Kyle Patch, Sebastian Porsdam-Mann, Gokul Raj, Khaleel Rajwani, Keisha Ray, William Smith, Daniel Villiger, Neil Levy, Roger Crisp, Julian Savulescu, Ilina Singh, David B Yaden
No abstract text is available yet for this article.
May 2, 2024: American Journal of Bioethics: AJOB
https://read.qxmd.com/read/38694265/is-use-of-psychedelic-drugs-a-risk-or-protective-factor-for-late-life-cognitive-decline
#8
JOURNAL ARTICLE
Kaeleigh Fearn, Kallol Kumar Bhattacharyya
Objectives: Common age-related health conditions can lead to poor mental health outcomes and deteriorate cognition. Additionally, commonly prescribed medications for various mental/physical health conditions may cause adverse reactions, especially among older adults. Psychedelic therapy has shown positive impacts on cognition and has been successful in treating various mental health problems without long-lasting adversities. The current study examines the association between psychedelic drug usage and cognitive functions in middle-aged and older adults...
2024: Gerontology & Geriatric Medicine
https://read.qxmd.com/read/38693554/n-n-dimethyltryptamine-a-natural-hallucinogen-ameliorates-alzheimer-s-disease-by-restoring-neuronal-sigma-1-receptor-mediated-endoplasmic-reticulum-mitochondria-crosstalk
#9
JOURNAL ARTICLE
Dan Cheng, Zhuo-Gui Lei, Kin Chu, Oi Jin Honey Lam, Chun Yuan Chiang, Zhang-Jin Zhang
BACKGROUND: Aberrant neuronal Sigma-1 receptor (Sig-1r)-mediated endoplasmic reticulum (ER)- mitochondria signaling plays a key role in the neuronal cytopathology of Alzheimer's disease (AD). The natural psychedelic N, N-dimethyltryptamine (DMT) is a Sig-1r agonist that may have the anti-AD potential through protecting neuronal ER-mitochondrial interplay. METHODS: 3×TG-AD transgenic mice were administered with chronic DMT (2 mg/kg) for 3 weeks and then performed water maze test...
May 1, 2024: Alzheimer's Research & Therapy
https://read.qxmd.com/read/38692686/efficacy-of-psilocybin-for-treating-symptoms-of-depression-systematic-review-and-meta-analysis
#10
REVIEW
Athina-Marina Metaxa, Mike Clarke
OBJECTIVE: To determine the efficacy of psilocybin as an antidepressant compared with placebo or non-psychoactive drugs. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Five electronic databases of published literature (Cochrane Central Register of Controlled Trials, Medline, Embase, Science Citation Index and Conference Proceedings Citation Index, and PsycInfo) and four databases of unpublished and international literature (ClinicalTrials...
May 1, 2024: BMJ: British Medical Journal
https://read.qxmd.com/read/38687360/content-analysis-of-reddit-posts-about-coadministration-of-selective-serotonin-reuptake-inhibitors-and-psilocybin-mushrooms
#11
JOURNAL ARTICLE
Kimberly Sakai, Ellen R Bradley, Joseph A Zamaria, Gabrielle Agin-Liebes, D Parker Kelley, Alexander Fish, Valeria Martini, Michelle C Ferris, Emma Morton, Erin E Michalak, Aoife O'Donovan, Joshua D Woolley
RATIONALE: Treatments with the serotonergic psychedelic psilocybin are being investigated for multiple neuropsychiatric disorders. Because many patients with these disorders use selective serotonin reuptake inhibitors (SSRIs), understanding interactions between psilocybin and SSRIs is critical for evaluating the safety, efficacy, and scalability of psilocybin-based treatments. Current knowledge about these interactions is limited, as most clinical psilocybin research has prohibited concomittant SSRI use...
April 30, 2024: Psychopharmacology
https://read.qxmd.com/read/38683460/in-the-new-era-of-psychedelic-assisted-therapy-a-systematic-review-of-study-methodology-in-randomized-controlled-trials
#12
REVIEW
Paul S Soliman, Dallece E Curley, Christy Capone, Erica Eaton, Carolina L Haass-Koffler
Recent years have seen a resurgence in randomized, placebo controlled trials (RCTs) utilizing non-classical psychedelics (e.g. 3,4-methyl enedioxy methamphetamine [MDMA]), and classical psychedelics (e.g. psilocybin, lysergic acid diethylamide [LSD], and N,N-dimethyltryptamine [DMT/ayahuasca]) in conjunction with assisted therapy (AT) for psychiatric disorders. A notable methodological challenge in psychedelic AT, however, is the complexity of blinding procedures. The lack of efficacious blinding can introduce considerable response bias, reduce internal validity, and compromise participant retention...
April 29, 2024: Psychopharmacology
https://read.qxmd.com/read/38680419/psychedelic-skepticism-back-to-the-sixties
#13
JOURNAL ARTICLE
Eduardo Ekman Schenberg
No abstract text is available yet for this article.
2024: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/38666447/making-1-h-1-h-couplings-more-accessible-and-accurate-with-selective-2dj-nmr-experiments-aided-by-13-c-satellites
#14
JOURNAL ARTICLE
François-Xavier Cantrelle, Emmanuelle Boll, Davy Sinnaeve
1 H-1 H coupling constants are one of the primary sources of information for nuclear magnetic resonance (NMR) structural analysis. Several selective 2DJ experiments have been proposed that allow for their individual measurement at pure shift resolution. However, all of these experiments fail in the not uncommon case when coupled protons have very close chemical shifts. First, the coupling between protons with overlapping multiplets is inaccessible due to the inability of a frequency-selective pulse to invert just one of them...
April 26, 2024: Analytical Chemistry
https://read.qxmd.com/read/38666090/long-term-benefits-to-psychological-health-and-well-being-after-ceremonial-use-of-ayahuasca-in-middle-eastern-and-north-african-immigrants-and-refugees
#15
JOURNAL ARTICLE
Matthew X Lowe, Hannes Kettner, Del R P Jolly, Robin L Carhart-Harris, Heather Jackson
BACKGROUND: Refugees and immigrants can experience complex stressors from the process of immigration that can have lasting and severe long-term mental health consequences. Experiences after ayahuasca ingestion are shown to produce positive effects on psychological wellbeing and mental health, including anecdotal reports of improved symptoms of trauma and related disorders. However, data on the longitudinal health impact of naturalistic ayahuasca use in Middle Eastern and North African (MENA) immigrant and refugee populations is limited...
2024: Frontiers in Psychiatry
https://read.qxmd.com/read/38665888/feasibility-and-effectiveness-study-of-applying-a-hallucinogen-harm-reduction-and-integration-model-to-a-mindfulness-thinking-intervention-using-virtual-reality-a-randomized-controlled-trial
#16
JOURNAL ARTICLE
Yanying Chen, Tianyang Wang, Yuxi Tan, Duo Li
OBJECTIVE: The purpose of this study was to investigate whether a virtual reality (VR) program designed and developed based on the hallucinogenic harm reduction and integration (PHRI) clinical model could be more effective in guiding positive thinking training, improving positive thinking awareness and ability, and, to some extent, facilitating personal efficacy and emotional state compared to a traditional VR program that places users in a virtual natural ecological environment to guide positive thinking training...
2024: Digital Health
https://read.qxmd.com/read/38664850/genetic-regulation-of-l-tryptophan-metabolism-in-psilocybe-mexicana-supports-psilocybin-biosynthesis
#17
JOURNAL ARTICLE
Paula Sophie Seibold, Sebastian Dörner, Janis Fricke, Tim Schäfer, Christine Beemelmanns, Dirk Hoffmeister
BACKGROUND: Although Basidiomycota produce pharmaceutically and ecologically relevant natural products, knowledge of how they coordinate their primary and secondary metabolism is virtually non-existent. Upon transition from vegetative mycelium to carpophore formation, mushrooms of the genus Psilocybe use L-tryptophan to supply the biosynthesis of the psychedelic tryptamine alkaloid psilocybin with the scaffold, leading to a strongly increased demand for this particular amino acid as this alkaloid may account for up to 2% of the dry mass...
April 25, 2024: Fungal Biology and Biotechnology
https://read.qxmd.com/read/38662070/valuing-the-acute-subjective-experience
#18
JOURNAL ARTICLE
Katherine Cheung, Brian D Earp, David B Yaden
Psychedelics, including psilocybin, and other consciousness-altering compounds such as 3,4-methylenedioxymethamphetamine (MDMA), currently are being scientifically investigated for their potential therapeutic uses, with a primary focus on measurable outcomes: for example, alleviation of symptoms or increases in self-reported well-being. Accordingly, much recent discussion about the possible value of these substances has turned on estimates of the magnitude and duration of persisting positive effects in comparison to harms...
2024: Perspectives in Biology and Medicine
https://read.qxmd.com/read/38662069/are-psychedelic-experiences-transformative-can-we-consent-to-them
#19
JOURNAL ARTICLE
Brent M Kious, Andrew Peterson, Amy L McGuire
Psychedelic substances have great promise for the treatment of many conditions, and they are the subject of intensive research. As with other medical treatments, both research and clinical use of psychedelics depend on our ability to ensure informed consent by patients and research participants. However, some have argued that informed consent for psychedelic use may be impossible, because psychedelic experiences can be transformative in the sense articulated by L. A. Paul (2014). For Paul, transformative experiences involve either the acquisition of knowledge that cannot be obtained in any other way or changes in the self...
2024: Perspectives in Biology and Medicine
https://read.qxmd.com/read/38662068/bio-psycho-spiritual-perspectives-on-psychedelics-clinical-and-ethical-implications
#20
REVIEW
Logan Neitzke-Spruill, Nese Devenot, Dominic Sisti, Lynnette A Averill, Amy L McGuire
Psychedelics have again become a subject of widespread interest, owing to the reinvigoration of research into their traditional uses, possible medical applications, and social implications. As evidence for psychedelics' clinical potential mounts, the field has increasingly focused on searching for mechanisms to explain the effects of psychedelics and therapeutic efficacy of psychedelic-assisted therapy (PAT). This paper reviews three general frameworks that encompass several prominent models for understanding psychedelics' effects-specifically, neurobiological, psychological, and spiritual frameworks...
2024: Perspectives in Biology and Medicine
keyword
keyword
674
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.